CRBP - Corbus Pharmaceuticals Holdings, Inc.

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Show:
Balance sheet
Cash flow
Annual

Income statement

All numbers in thousands
Breakdown
ttm
31/12/2022
31/12/2021
31/12/2020
31/12/2019
Total revenue
0
0
881.705
3,937
36,144
Operating expenses
Research development
16,137
16,137
36,445
98,267
89,605
Selling general and administrative
18,699
18,699
20,425
28,480
23,643
Total operating expenses
34,835
34,835
56,871
126,747
113,248
Operating income or loss
-34,835
-34,835
-55,989
-122,810
-77,105
Total other income/expenses net
-5,379
-5,379
12,179
12,569
4,423
Income before tax
-42,347
-42,347
-45,640
-111,269
-71,454
Income from continuing operations
-42,347
-42,347
-45,640
-111,269
-71,454
Net income
-42,347
-42,347
-45,640
-111,269
-71,454
Net income available to common shareholders
-42,347
-42,347
-45,640
-111,269
-71,454
Basic EPS
-
-10.15
-11.10
-42.60
-33.60
Diluted EPS
-
-10.15
-11.10
-42.60
-33.60
Basic average shares
-
4,171
4,100
2,604
2,130
Diluted average shares
-
4,171
4,100
2,604
2,130
EBITDA
-
-34,835
-55,989
-122,810
-77,105